Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Zentalis Pharmaceuticals (ZNTL) Stock Falls -42% in 30 Days as Downtrend Persists

Zentalis Pharmaceuticals (ZNTL) Stock Falls -42% in 30 Days as Downtrend Persists

Key Takeaways

  • ZNTL shares fell roughly 42% over the last 30 days, sliding from about $2.36 to approximately $1.37.
  • The decline extends a broader multi-month downtrend, with the stock down roughly 64% over the past quarter.
  • Encouraging overall survival data from the DENALI trial presented at ESMO 2026 and several analyst upgrades were not enough to reverse the slide.
  • An August follow-on equity offering and ongoing operating losses continue to weigh on investor sentiment.
  • The next major clinical catalyst is the integrated DENALI Part 2 topline readout, expected in the first half of 2027.
  • Get more detail on ZNTL's Price Targets, Earnings, and Forecasts on dedicated pages.

Company Background and Strategy

Zentalis Pharmaceuticals is a clinical-stage oncology company focused on developing azenosertib, an investigational, potentially first-in-class oral WEE1 inhibitor. The company's strategy centers on biomarker-driven treatment, with its lead program targeting Cyclin E1-positive platinum-resistant ovarian cancer. Azenosertib is being evaluated across multiple trials, including the DENALI registrational program and the Phase 3 ASPENOVA study. As a pre-revenue biopharmaceutical developer, Zentalis is closely followed by investors for clinical data readouts, regulatory milestones, and its cash runway rather than conventional revenue growth. I checked comparable names in the space using Tickeron’s AI Screener to see how ZNTL stacks up on key metrics.

Stock Price Performance Over the Past Month and Quarter

Over the last 30 days, ZNTL has declined roughly 42%, falling from a closing price of about $2.36 in mid-to-late October to approximately $1.37 in mid-November. The move has been largely one-directional, characterized by lower highs and lower lows rather than a single sharp gap. The quarterly picture is even steeper. Approximately three months ago, shares traded near $3.84, meaning the stock has lost roughly 64% of its value over the trailing quarter. The slide began in earnest after an August 2026 follow-on offering priced at $3.50 per share, and the stock has continued to drift lower through September, October, and November despite a series of clinical and analyst-driven developments.

Drivers of the Recent 30-Day Decline

The 30-day decline occurred even as the company reported clinical progress. In October 2026, Zentalis presented DENALI Part 1b overall survival data at the ESMO Congress, showing a median overall survival of 15.9 months in Cyclin E1-positive patients versus 7.5 months in Cyclin E1-negative patients, along with an updated response rate of 37.2%. Wedbush upgraded the stock to Outperform with a $6 price target, and Leerink initiated coverage with an Outperform rating. Despite these positive signals, the shares kept falling. The most likely contributors were the lingering overhang from the August equity raise, which diluted existing holders, ongoing operating losses, and a long wait until the integrated DENALI Part 2 topline in the first half of 2027. Third-quarter results reported on November 9, 2026, showed a net loss of $28.8 million, reinforcing the reality of continued cash burn even as the company reported $228.9 million in cash and a runway into the first half of 2028. Weak technical positioning and a risk-off tone across smaller-cap biotechnology names compounded the pressure.

Quarterly Downtrend and Financing Impact

The quarterly downtrend traces back to the company's August 2026 financing. Zentalis completed a follow-on offering of 26.45 million shares at $3.50 per share, raising approximately $86.9 million in net proceeds to fund its clinical programs. While the raise extended the cash runway, it also repriced the stock and reset investor expectations. From there, shares steadily ground lower into the autumn. Over the quarter, the broader narrative has been one of a well-funded but pre-revenue biotech waiting for definitive data. Enrollment in DENALI Parts 2a and 2b was completed, with Part 2c expected to finish in November 2026, but the pivotal integrated readout remains months away. That gap between near-term milestones and the next major binary event left the stock vulnerable to sustained selling pressure throughout the period.

Key Catalysts on the Horizon

Looking ahead, the most important variable for ZNTL is the integrated DENALI Part 2 topline readout, which management has guided to the first half of 2027. Investors will also monitor completion of DENALI Part 2c enrollment and continued progress in the Phase 3 ASPENOVA trial. On the financial side, the company's cash position of $228.9 million, expected to fund operations into the first half of 2028, reduces near-term financing risk but does not eliminate it. Other factors to watch include the regulatory landscape for accelerated approvals in oncology, competitive developments in the ovarian cancer treatment space, and broader sentiment toward smaller-cap biotechnology names. Analyst price targets remain above current trading levels, but the gap between those targets and the stock's recent weakness underscores the uncertainty surrounding the pivotal data. As with any clinical-stage company, the outcome of key trial readouts will be the dominant driver of the share price. I’m watching this closely as the data timeline approaches.

AI Tools in Biotech Research

From what I see, automated strategies can help cut through the noise in volatile names like this. I’ve been testing Tickeron’s AI Trading Bots to model different scenarios around clinical catalysts and see how they might perform across market conditions. The platform lets users review a range of approaches and performance metrics, which can be useful when evaluating exposure to pre-revenue biotechs.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ZNTL

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


ZNTL's Stochastic Oscillator stays in oversold zone for 4 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

Following a +8.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZNTL advanced for three days, in 210 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

ZNTL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for ZNTL turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 40 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZNTL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for ZNTL entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.134) is normal, around the industry mean (3.596). P/E Ratio (-0.878) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (6.812) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. ZNTL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZNTL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -16%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company, which focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer

Industry Biotechnology

Industry
N/A
Address
10275 Science Center Drive
Phone
+1 858 263-4333
Employees
106
Web
https://www.zentalis.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.